Advantages of targeting B cell receptor complex to treat B-cell derived autoimmune diseases and lymphomas

Show full item record



Permalink

http://hdl.handle.net/10138/297919

Citation

Adem , J , Eray , M , Eeva , J , Nuutinen , U & Pelkonen , J 2017 , ' Advantages of targeting B cell receptor complex to treat B-cell derived autoimmune diseases and lymphomas ' , Molecular Immunology , vol. 88 , pp. 135-137 . https://doi.org/10.1016/j.molimm.2017.05.023

Title: Advantages of targeting B cell receptor complex to treat B-cell derived autoimmune diseases and lymphomas
Author: Adem, Jemal; Eray, Mine; Eeva, Jonna; Nuutinen, Ulla; Pelkonen, Jukka
Contributor: University of Helsinki, HUSLAB
Date: 2017-08
Language: eng
Number of pages: 3
Belongs to series: Molecular Immunology
ISSN: 0161-5890
URI: http://hdl.handle.net/10138/297919
Abstract: Antibodies produced by B-cells provide protection from infectious agents. However, impaired cell death signaling pathways in B-cells can lead to cancer, immunodeficiency or autoimmune diseases. B-cell signaling molecules such as CD20, CD19, Btk, and BAFF-R are targeted by therapeutic drugs and used to treat B-cell derived lymphomas or autoimmune diseases. Nevertheless, B-cells could develop resistance to these therapeutic drugs or the therapeutic drugs may have off-target effects. For instance, repeated rituximab (anti-CD20 antibody) treatment may lead to the loss of its target cell surface molecule, CD20. In addition, in B-cell malignancies, loss of CD19 expression has been observed. Another target molecule, Btk is expressed not only in B-cells but also in mast cells, macrophages, and dendritic cells. Thus, targeting Btk could negatively regulate the functions of innate immunity. The expression of BAFF-R is thought to be restricted to B-cells but it is also expressed on T cells. Targeting BAFF-R, therefore, may lead to depletion of T-cells in addition to B-cells. B cell receptor (BCR) expression and signaling, however, are critically important for development, differentiation and survival of B cells. Moreover, BCR is exclusively expressed on B-cells, which makes it an excellent target to avoid off-target effects.
Subject: BCR
Rituximab
CD20
BAFF-R
Autoimmune diseases
Lymphoma
3121 General medicine, internal medicine and other clinical medicine
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0161589017301578_main.pdf 122.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record